Protocol Ledger

NCT05562947 · Phase III · ACTIVE NOT RECRUITING

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Interventional Phase III clinical trial protocol NCT05562947 sponsored by Roche / Genentech in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-17 Enrollment: 68 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05562947
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)68 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05562947
Protocol FieldVerified Registry Value
NCT IdentifierNCT05562947
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment68 participants (ESTIMATED)
Registered Start Date2024-06-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05562947
Hospital Research SiteLocationSite Profile
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
West China Hospital,Sichuan UniversityChengdu, ChinaOpen Hospital Dossier ->
Sichuan Provincial People's HospitalChengdu, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI